Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
2017 Carnegie Science Awards Category: Life Sciences Additional Categories: Nominee Name: John Kellum MD Title: Professor of Critical Care Medicine, Medicine, Bioengineering and Clinical Translational Science Organization: University of Pittsburgh, Department of Critical Care Medicine Address: Room 604, Scaife Hall 3550 Terrance Street Pittsburgh, PA 15261 Phone Number: (412) 647-7810 Email: [email protected] Nominator Name: William Federspiel PhD Title: Professor-Department of Bioengineering, Chemical Engineering Organization: University of Pittsburgh Address: 302E Benedum Hall 3700 O’Hare Street Pittsburgh, PA 15261 Phone Number: (412) 383-9499 Email: [email protected] Personal Narrative In 150 words or less, please provide a brief statement of why the nominee excels relative to the award category. Dr. Kellum is physician-scientist who is internationally recognized for his pioneering advances in science, and translation of scientific discoveries to clinical products and procedures. He is Vice Chair for Research, and Director of the Center for Critical Care Nephrology, Department of Critical Care Medicine at the University of Pittsburgh. Dr. Kellum has led a world-wide effort to define acute kidney injury (AKI) and establish diagnostics and therapeutics for this condition that kills more than 3 million people annually. Among his many accomplishments include development of the first international consensus definitions for AKI known as the RIFLE criteria, serving as co-chair for the Kidney Disease Improving Global Outcomes (KDIGO) AKI workgroup that produced the first comprehensive clinical practice guideline for AKI, leading the clinical studies that culminated in the first FDA approved biomarker for AKI (Nephrocheck), and pioneering novel treatments for AKI including immune modulation, mitochondrial resuscitation and remote ischemic preconditioning. Achievements Please identify the novel, innovative, and unique achievement(s) relative to the award category you are submitting this nomination. Dr. Kellum is a prolific and highly cited author (over 25,000 citations and an h-index of 72). As noted above, he has a superb record of translating advancements in science into practical activities and tools. As an example, he was the lead investigator of a now FDA-approved lab test that will be used to help determine if critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury (AKI) in the 12 hours following the administration of the test. Early knowledge that a patient is likely to develop AKI may prompt closer patient monitoring and help prevent permanent kidney damage or death. This is significant as many physicians are aware of the need to assess patient risk for AKI, however until this development there has not been a reliable method of performing this risk assessment. 2017 Carnegie Science Awards Some of his most significant contributions to the literature include: Bihorac A, Chawla LS, Shaw AD, Al-Khafaji A, Davison DL, Demuth GE, et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. American Journal of Respiratory and Critical Care Medicine, 2014 189(8), 932–939. PMID:24559465 Zarbock A, Schmidt C, Van Aken H, Wempe C, Martens S, Zahn PK, Wolf B, Goebel U, Schwer CI, Rosenberger P, Haeberle H, Görlich D, Kellum JA, Meersch M. Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial. JAMA 2015 Jun 2;313(21):2133–41. PMID: 26024502 Regional Impact Please describe the impact of the candidate’s contributions to the Western Pennsylvania region. John's work has brought great attention to the need for, and the benefits of the state-of-the-art clinical care that is available in the region. He collaborates with clinicians in other departments at UPMC in the assessment and care of critically ill patients suffering with potentially debilitating kidney disease. Dr. Kellum has always performed his research with a particular focus on translating therapies to patients, and as such he has made significant efforts to reach out to the community through programming to inform patients and their loved ones of the research being done at the University of Pittsburgh that may one day lead to improved treatments. John and his team recently developed an “ap” for smart phones and pads that allows patients who have sustained AKI to keep track of their kidney function and medications that might harm them. The National Kidney Foundation is working with Dr. Kellum to promote the ap. Finally, Dr. Kellum works with high school and university students from the region to train and inspire the next generation of scientists. Impact Beyond the Region Please describe the impact of the candidate’s contributions outside of the Western Pennsylvania region. John is highly sought after for his expertise in a number of domains. As noted above, he routinely collaborates with peers across the US and in other countries, in the development and assessment of innovative therapies. Dr. Kellum is a past president of the Acute Disease Quality Initiative (www.adqi.org), an international, interdisciplinary group that publishes research and practice recommendations in critical care nephrology. He has led multiple national and international studies and continues to mentor research teams in Belgium, Germany, Brazil and China. He holds an Adjunct Professorship, at Shandong University, in Jinan, China. Examples Please upload work examples of the nominee. Please see addendum. Additional Information Please add any additional information that you feel would be relevant for consideration. While the listed accomplishments are applicable to AKI, they have broad-based interests and applicability. Dr. Kellum’s work in the biomarker field began as Co-PI of GenIMS (Genetic and Inflammatory Markers of Sepsis R01GM61992) the first large epidemiologic study of sepsis secondary to 2017 Carnegie Science Awards community-acquired pneumonia that characterized the inflammatory mediatory profiles and their relationship to outcomes. As PI of Biomarkers of Recovery for the Kidney (BioMaRK), he led a team of investigators who evaluated numerous markers for recovery after severe AKI. Finally, he led a discovery and validation effort for acute kidney injury biomarkers that culminated in the first diagnostic to receive U.S. Food and Drug Administration approval. Perhaps more importantly though, the biomarkers discovered appear to modulate cell-cycle progression in renal tubular epithelial cells and represent exciting new targets for therapy including remote ischemic preconditioning. Dr. Kellum is a pioneer in the treatment of sepsis. His work in AKI, sepsis and blood purification has been intertwined. He has provided much of preclinical data evaluating sorbents as blood purification modalities in sepsis. This work has opened numerous new avenues to approach the problem of sepsis by removal of damage and pathogen-associated molecular patterns to reprograming the immune response by manipulating chemokine gradients. He has studied the long-term effects of sepsis not only on the kidney but on the inflammatory response and on coagulation. These studies have led directly to his current work on late effects of sepsis on risk for new infection and cardiovascular events. Dr. Kellum has seven issued U.S. patents; nine pending patent applications and three additional invention disclosures.